

CoV2 Nucleocapsid Polyclonal

Full Length CoV2 Nucleocapsid, Polyclonal Antibody
ABP0005

Product Overview

Name CoV2 Nucleocapsid Polyclonal

Description

Full Length CoV2 Nucleocapsid, Polyclonal Antibody

Introduction

A human infecting coronavirus (viral pneumonia) called 2019 novel coronavirus, 2019-nCoV was found in the fish market at the city of Wuhan, Hubei province of China on December 2019. The 2019-nCoV shares an 87% identity to the 2 bat-derived severe acute respiratory syndrome 2018 SARS-CoV-2 located in Zhoushan of eastern China. 2019-nCoV has an analogous receptor-BD-structure to that of 2018 SARS-CoV, even though there is a.a. diversity so thus the 2019-nCoV might bind to ACE2 receptor protein (angiotensin-converting enzyme 2) in humans. On November 2021, WHO designated a variant of concern, named Omicron. Omicron has several mutations that may have an impact on how it behaves (how easily it spreads, the severity of illness).

Source

Escherichia Coli.

Physical Appearance

Sterile Filtered clear solution.

Formulation

CoV-2 Omicron protein solution (2.18mg/ml) is supplied in PBS and 25mM K₂CO₃.

Stability

Protein is shipped on ice packs. Upon arrival, Store at -20°C.

Purity

Protein is >95% pure as determined SDS-PAGE.

Amino acid sequence

HMSDNGPQNN RNALRITFGG PSDSTGSNNQ GEARSQRRP QGLPNNTASW FTALTQHGKE DLKFPRGQGV
PINTNSSPDD QIGYYRRATR RIRGGDGKMK ELSPRWYFYY LGTGPEAGLP YGANKDGIW VATEGALNTP
KDHIQTRNPA NNAIVLQLP QGTTLPKGFY AEGSRGGSQA SSRSSSRN SSRNSTPGSS KRTSPARMAG
NGGDAALALL LLDRLNQLES KMSGKGQQQQ GQTVTKKSAA EASKKPRQKRT ATKAYNVTQA FGRRGPEQTQ
GNFGDQELIR QGTDYKHWPQ IAQFAPSASA FFGMSRIGME VTPSGTWLTY TGAIKLDDKD PNFKDQVILL
NKHIDAYKTF PPTEPKKDKK KKADETQALP QRQKKQQTVT LLPAADLDDF SKQLQQSMSS ADSTQA

Precautions

CoV2 Nucleocapsid Polyclonal is for research use only and not for use in diagnostic or therapeutic procedures.